SBIR/STTR Research Award
A Novel Peptide Therapeutic for Obesity
Award amount
$224,700Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- VIRTICI LLC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- V29SWGG4MQ64
- Solicitation number
- PA13-234
- Topic code
- NIDDK
Research abstract
DESCRIPTION (provided by applicant): The goal of this project is to develop a novel peptide therapeutic, GLP-1-5, for the treatment of obesity. Today, one-third of adults in the United States (US) are obese, with an estimated annual healthcare burden of approximately 150 billion. By 2030, it is projected that over 50% of adults in the US will be obese with a yearly healthcare burden expected to exceed 860 billion, which will account for approximately 18% of the total US health-care costs. GLP-1 is a glucoincretin hormone that augments glucose-dependent insulin secretion. We discovered that the administration of GLP-1(9-36)amide, the major form of GLP-1 present in the circulation, leads to the formation of two peptides; a nonapeptide, GLP-1(28-36)amide (referred to as GLP-1-9) and a pentapeptide, GLP-1(32- 36)amide (referred to as GLP-1-5) in mouse plasma within 5 minutes. Both of these peptides are the product of GLP-1 cleavage by neprilysin, and both appear to act by a different mechanism than existin
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- A Novel Anti-infective Therapy for Treating Periodontitis
- A Novel Peptide for the Oral Treatment and Prevention of P. Gingivalis Infection
- A Novel Blood Test for Early Diagnosis of Frontotemporal Lobar Degeneration
- A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis
- A Novel Sublingual Vaccine to Prevent Neisseria Gonorrhoeae Infection
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- ND Enabling Studies for CMT-101, a Novel Gene Therapy for Glycogen Storage Disease 1b
- Wearable Metabolic Sensor for Monitoring of Lactate and Glucose for People with Diabetes
- Novel Over-the-Scope Platform for Control of Variceal Bleeding
- Tolerogenic Nanotherapy to Delay Type I Diabetes
- An intravascular Bioartificial Pancreas (iBAP)
Research funding history
32 SBIR/STTR records share this UEI (2012–2025). Reported award amounts total $25,565,534. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services